Chang-Claude from the German Tumor Research Middle in Heidelberg, were released in Springer's Journal of Malignancy Survivorship. Obi's research group set out to identify risk elements that could result in the development of heart disease, osteoporosis and hypertension in breast cancer survivors. They therefore assessed medical status of 2,542 breast cancer patients between 50 and 74 years aged who were area of the Mamma carcinoma Risk element Investigation study in the town and condition of Hamburg and the Rhine-Neckar Karlsruhe region in Germany. Patients were asked about their health issues before and after becoming diagnosed with breast cancer.‘The immune response data reported today provide added support for the idea that a whole-cell immunotherapy, such as GVAX immunotherapy for prostate malignancy, can be an ideal multi-antigen source that is capable of eliciting an immune response to a wide selection of tumor-associated antigens,’ mentioned Peter K. Working, Ph.D., senior vice president of Advancement and Research at Cell Genesys. ‘That the majority of antibody responses are exclusive to individual individuals is further proof that the non patient-specific format of GVAX immunotherapies is usually capable of inducing unique, patient-specific immune responses. Furthermore, the known fact that many of the antigens have not before been connected with prostate cancer, further shows that a multivalent antigen immunotherapy like GVAX immunotherapy may provide the best prospect of inducing an effective anti-tumor immune response, especially for heterogeneous cancers such as for example prostate cancer.’ Related StoriesSausages With Antioxidants From Berries TO AVOID CancerCornell biomedical engineers develop 'super natural killer cells' to destroy malignancy cells in lymph nodesMeat-rich diet may boost kidney cancer riskEvidence of patient-particular immune responses associated with non patient – particular GVAX immunotherapy products in addition has been reported in additional cancers.